Cargando…
Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands
Dendritic cell (DC) vaccines have proven to be a valuable tool in cancer immune therapy. With several DC vaccines being currently tested in clinical trials, knowledge about their therapeutic value has been significantly increased in the past decade. Despite their established safety, it has become cl...
Autores principales: | Versteven, Maarten, Flumens, Donovan, Campillo-Davó, Diana, De Reu, Hans, Van Bruggen, Laura, Peeters, Stefanie, Van Tendeloo, Viggo, Berneman, Zwi, Dolstra, Harry, Anguille, Sébastien, Hobo, Willemijn, Smits, Evelien, Lion, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891487/ https://www.ncbi.nlm.nih.gov/pubmed/35250967 http://dx.doi.org/10.3389/fimmu.2022.734256 |
Ejemplares similares
-
In vitro expansion of Wilms’ tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells
por: van der Heijden, Sanne, et al.
Publicado: (2023) -
The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy
por: Campillo-Davo, Diana, et al.
Publicado: (2021) -
Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
por: Campillo-Davo, Diana, et al.
Publicado: (2020) -
Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
por: Van Acker, Heleen H., et al.
Publicado: (2019) -
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
por: Roex, Gils, et al.
Publicado: (2022)